ALS is a devastating disease affecting a wide range of individuals, from young adults to senior citizens. The progressive and highly debilitating nature of the disease, combined with the lack of effective therapeutics, makes it a prime target for stem cell therapy. The unique functional properties of stem cells make them particularly promising for neurodegenerative diseases, and as a result, a number of stem cell clinical trials are underway in this area, both allogeneic and autologous. While these trials are only in their early stages, and there is still much work to be done, Adrian Harel at BrainStorm Cell Therapeutics explores how the challenges lying ahead will be overcome, bringing us closer each day to conquering ALS.
 http://jforcs.com/jcs/wp-content/uploads/edd/2012/09/Pages-from-JCS-Volume4Issue5.pdf